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Abstract
Individual perception of vaccine safety is an important factor in determining a
person's adherence to a vaccination program and its consequences for disease
control. This perception, or belief, about the safety of a given vaccine, is not
a static parameter but a variable subject to environmental influence. To com-
plicate matters, perception of risk (or safety) does not correspond to actual
risk. In this paper we propose a way to model the dynamics of such beliefs in
the context of a realistic epidemiological scenario. The methodology proposed
is based on Bayesian inference, and can be extended to model more complex
belief systems associated with decision models.
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Introduction
Since early vaccination campaigns against smallpox, vaccination policies have
been a matter of debate10: mass vaccination versus blocking strategies; compul-
sory versus voluntary, are some highly debated issues. Despite these early con-
troversies - and consequent alternative policies implemented in different coun-
tries - high disease scare in the past has led to very high vaccine coverage and
consequent successful eradication of smallpox, as well as very low incidence of
measles, polio, tetanus, diphtheria, etc, resulting in over 98% mortality reduc-
tion by vaccine preventable diseases in developed countries7.
In recent years, after complete or almost complete elimination of these dis-
eases, the debate is shifting towards issues of vaccine safety. Increased percep-
tion of vaccine risks and lowered perception of disease risks has challenged pre-
vious willingness to vaccinate (fundamental for the success of any immunization
program, either voluntary or compulsory)14. In this scenario, understanding
and predicting individual's willingness to vaccinate is paramount for estimating
vaccine coverage and compare strategies to achieve coverage goals.
Willingness to vaccinate is highly dependent on the perceived risk of acquir-
ing a serious disease15. When (perceived) disease risk is low, however small risk
of adverse events from the vaccine become relatively important and may lead
to vaccine coverage lower than required to control transmission15. When (per-
ceived) serious disease risk is too high, on the other hand, vaccine coverage may
increase above that required to guarantee population protection3. We illustrate
these behaviors with two examples:
The MMR vaccine scare In the UK, MMR vaccine uptake started to de-
cline after a controversial study linking MMR vaccine to autism9. In a decade,
vaccine coverage went well below the target herd immunity level of 95%. De-
spite the confidence of researchers and most health professionals on the vaccine
safety, the confidence of the public was deeply affected. In an attempt to find
ways to restore this confidence, several studies were carried out to identify fac-
tors associated with parent's unwillingness to vaccinate their children. They
found that 'Not receiving unbiased and adequate information from health pro-
fessionals about vaccine safety' and 'media's adverse publicity' were the most
common reasons influencing uptake12. Other important factors were: 'lack of
belief in information from the government sources'; 'fear of general practition-
ers promoting the vaccine for personal reasons'; and 'media scare'. Note that
during this period the risk of acquiring measles was very low due to previously
high vaccination coverage.
The Brazilian Yellow Fever disease scare Sylvatic yellow fever (SYF) is
a zoonotic disease, endemic in the north and central regions of Brazil. Approxi-
mately 10% of infections with this flavivirus are severe and result in hemorrhagic
fever, with case fatality of 50%6. Since the re-introduction of A. aegypti in Brazil
(the urban vector of dengue and yellow fever), the potential reemergence of ur-
ban yellow fever is of concern5. In Brazil, it is estimated that approximately 95%
of the population living in the yellow fever endemic regions have been vaccinated.
In this area, small outbreaks occur periodically, especially during the rainy sea-
son, and larger ones are observed every 7 to 10 years11, in response to increased
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Figure 1: Yellow fever cases, vaccination coverage, and adverse vaccination
events. Coverage data is from Brasilia (DF), which was the epicenter of the
outbreak.
viral activity within the environmental reservoir. In 2007, increased detection
of dead monkeys in the endemic zone, led the government to implement vac-
cine campaigns targeting travellers to these areas and the small fraction of the
resident population who were still not protected by the vaccine. The goal was
to vaccinate 10 - 15% of the local population. Intense notification in the press
regarding the death of monkeys near urban areas, and intense coverage of all sub-
sequent suspected and confirmed human cases and death events led to an almost
country-wide disease scare, incompatible with the real risks3, which caused se-
rious economic and health management problems, including waste of doses with
already immunized people (60% of the population was vaccinated when only
10-15% would be sufficient), adverse events from over vaccination (individuals
taking multiple doses to 'guarantee' protection), national vaccine shortage and
international vaccine shortage, since Brazil stopped exporting YF vaccine to
supply domestic vaccination rush (www.who.int/csr/don/2008_02_07/en/).
The importance of public perceptions and collective behavior for the out-
come of immunization campaigns are starting to be acknowledged by theoreti-
cians2,13,5. These factors have been examined in a game theoretical framework,
where the influence of certain types of vaccinating behaviour on the stability
and equilibria of epidemic models is analyzed.
In the present work, we propose a model for individual immunization be-
havior as an inference problem: Instead of working with fixed behaviors, we
develop a dynamic model of belief update, which in turn determines individual
behavior.
An individual's willingness to vaccinate is derived from his perception of
disease risk and vaccine safety, which is updated in a Bayesian framework, ac-
cording the epidemiological facts each individual is exposed to, in their daily
life. We also explore the global effects of individual decisions on vaccination
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adherence at the population level.
In summary, we propose a framework to integrate dynamic modeling of
learning (belief updating) with decision and population dynamics.
Methods
We set the vaccination decision problem in the context of a population experi-
encing a vaccine preventable disease outbreak which leads to a mass vaccination
campaign. Individuals receive information regarding vaccine and disease events
from local and global sources. We assume that 'good' events (prompt recovery
from infection or safe vaccine events) are visible locally only while severe cases
of disease or potentially adverse events from the vaccine enjoy global visibility
due to the natural preference of media channels for scary stories. In order to
integrate behavioral and epidemiological dynamics, an individual based model
was developed. Individual's behavior regarding vaccination is represented in a
belief-decision model which describes the dynamics of belief updates in response
to epidemiological events and the decision making based on the person's current
beliefs. The epidemiological model determines the disease dynamics in a popu-
lation with hierarchical contact structure, representing a large urban setting.
Belief Model
The belief model describes the temporal evolution of each individual's willing-
ness to vaccinate, vt, in response to his evaluation of vaccine safety and disease
risk. To account for the uncertainties regarding vaccinating behavior, vt is mod-
eled as a random variable, whose distribution is updated weekly as the individual
observes new events. The update process is based on logarithmically pooling vt
with other random variables as described below.
The belief update model takes the form:
vt+1 =
vα1t s
α2
t d
α3
t r
α4
t∫
vα1t s
α2
t d
α3
t r
α4
t
(1)
where α1 = α2 = 1/4 with remaining αi taking values according to the
following conditions: {
if nsd > 0 : α3 = 1/2, α4 = 0
otherwise : α3 = 0, α4 = 1/2
where nsd is the number of serious disease cases witnessed by the individ-
ual, and st and dt are random variables describing individual's belief regarding
vaccine safety and disease risk, respectively. Every individual starts off with a
very low expected value for vt : v0 ∼ Be(1, 20), E[v0] ≈ 0.047.
Since we assume that under no perceived disease risk, willingness to vaccinate
should decrease, the last term in (1), rt is a drift force which causes a reduction
in E[vt] up to the minimum value of E[v0].
Equation (1) combines the different beliefs through a logarithmic pooling8,
which is a standard way of combining probability distributions with the purpose
of obtaining a consensus of multiple beliefs. In this operation, the αi act as
weights, modifying the importance of each distribution, and must add up to
one8.
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Perceived vaccine safety (st): Regularly, during a mass vaccination cam-
paign, individuals will try to infer the value of vaccinating based on available
information regarding vaccine events. During a campaign, the number of safe
vaccine events, V can naturally be modeled as a binomial distributed variable,
with parameters η and pi standing for the number of doses given and the proba-
bility of safe event, respectively16. However, since data available to individuals
is biased and incomplete, the observed variable v that feeds each individual's
inferential process is a Binomial governed by n and s, the perceived number of
doses and perceived probability of a safe vaccine event, respectively:
V ∼ Bin(η, piv)
v ∼ Bin(n, s)
Note that v is not the true number of safe vaccine doses applied in the
population, but represents a subset of these events which the individual is aware
of. This means that the perceived safety of the vaccine will always be a biased
estimate, and will vary from individual to individual generating variation in the
population belief distribution.
Each individual will make inference of s based on n and v, This is modelled
as a iterative Bayesian inference. Let the prior distribution for st be a Be(α, β),
which is the natural conjugate for a binomial process. The posterior distribution
st+1 is then given by:
st+1(n, v) ∼ Be(α+ v, β + n− v) (2)
The posterior st+1 is used in the following iteration cycle as the prior.
To better emulate the biased availability of good versus bad news in real
populations, we assume that vaccine adverse events are visible globally, while
safe events are visible only within their neighborhoods. To include the effects of
an exaggerated media coverage of vaccine adverse events, we considered scenar-
ios where the the observed number of adverse events (n − v) is amplified by a
constant a in equation (2). We call this factor the media-amplification factor,
varying from 1 (no amplification) to 16.
Perceived disease risk (dt): In this model, we try to emulate a scary disease,
that is, a disease severe enough that a few cases will lead to a high willingness
to get a vaccine shot.
Disease scare is defined as an increase in the individual's vt, upon witnessing
disease cases with serious consequences. It must be noted, however, that this
probability refers to the decision of getting a vaccine, since effectively getting
vaccinated will also depend on the availability of the vaccine. This effect enters
vt update equation (1) as the variable dt ∼ Be(α, β), where:
α = E[dt]
(
E[dt](1− E[dt])
σ2
− 1
)
(3)
β = (1− E[dt])
(
E[dt](1− E[dt])
σ2
− 1
)
E[dt] = E[vt] + (1− E[vt])tanh(0.3nsd)
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Figure 2: Updating the perceived probability of a safe vaccination. The expected
value of st will change towards one with more safe vaccines witnessed and in
the opposite direction with the accumulation of VAE events.
where nsd is the number of serious disease cases witnessed. Figure 3 shows
how E[dt] varies with the number of serious disease cases witnessed. Serious
disease cases are visible globally. Here, dt has a fixed variance σ
2 = 0.005. The
pooling between vt and dt is done as in (1). In equation (1) α3 can be modified
to make the disease more or less scary to individuals.
Drift (rt): The drift is a slow but continuous reduction of the mean willingness
to vaccinate, vt towards its initial distribution vt=0. This will happen only in
the absence of perceived serious disease cases. The drift enter vt update cycle
as the variable rt in (1) and has a Beta distribution with mean given by:
E[rt] =
5E[vt] + E[v0]
6
and parameters derived from E[rt] in the same way as in (3).
Decision: Once a week, during the simulation, susceptible and exposed in-
dividuals decide whether to go vaccinate with a probability sampled from vt,
updated according to equations (1) and (2). This update is based on evidence
collected during the past seven days (figure 4).
Only non-infectious individuals make the decision to whether or not they
should go vaccinate. We consider that exposed individuals do not know they
have been infected, so they also may seek vaccination. This is important be-
cause there is a limited amount of vaccine doses available per week and exposed
individuals will compete with susceptibles for them. Only susceptibles are suc-
cessfully immunized by the vaccine.
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Figure 3: Mean scare as a function of Serious disease cases witnessed.
Figure 4: Daily and weekly events that determine individual activity. Movement
decisions take place on a daily basis.
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Figure 5: Design of the hierarchical population model. Arrows show the possible
patterns of daily movement of individuals.
Population model
We model disease spread in a hypothetical city represented by a multilevel
metapopulation individual-based model where individuals belong to groups that
in turn belong to groups of groups, and so on, forming a hierarchy of scales17.
In this hypothetical city, individuals live in households with exactly 4 members
each; neighborhoods are composed by 100 households and sets of 10 neighbor-
hoods form the city's zones. During the simulation, individuals commute be-
tween home and a randomly chosen neighborhood anywhere in the population
graph. Each individual has a probability 0.25 of leaving home daily.
This same hierarchical structure is used to define local and global events. Lo-
cally visible events can only be witnessed by people living in the same neighbor-
hood while globally visible events are visible to the entire population regardless
of place of residence.
Epidemiological Model
The epidemiological model describes a population being invaded by a new
pathogen. This pathogen causes an acute infection, lasting 11 days (incuba-
tion period of 6 days and an infectious period of 5 days). Once in the infectious
period, individuals have a fixed probability, psd of becoming seriously ill. After
recovery, individuals become fully immune. The proportion of the population in
each immunological state at time t is labeled as S(t), E(t), I(t) and R(t), which
stands for susceptibles, exposed, infectious and recovered states.
At the same time the disease is introduced in the population, a vaccination
campaign is started, making available nd doses per week to the entire population,
meaning that individuals may have to compete for a dose if many decide to
vaccinate at the same time.
Once an individual is vaccinated, if he/she has not been exposed yet, he/she
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Table 1: Parameter values used for the simulations.
Symbol Meaning Value
psd prob. of serious illness [10−6, 10−2]
(1− pi) prob. of vaccine adverse effects [10−6, 10−2]
βnh prob. of transmission/contact 0.2
βhh prob. of transmission/contact at home 0.3
c number of contacts per day 4
a media amplification factor [1, 16]
moves directly to the recovered class, with full immunity (thus, a perfect vaccine
is assumed). If the individual is in the incubation period of the disease, disease
progression is unaffected by vaccination. Vaccination carries with it a fixed
chance (pae = 1− pi) of causing adverse effects.
Transmission dynamics is modelled as follows: at each discrete time step, t =
1, 2, 3, ..., 70, each individual contacts others in two groups: in his residence and
in the public space. The probability of getting infected at home is given by p0 =
1−(1−βhh)ihh where βhh is the probability of transmission per household contact
and ihh is the number of infected members in the house. In the public space,
that is, in the neighborhood chosen as destination for the daily commutations,
each infected person contacts c persons at random, and if the contact is with a
susceptible, infection is transmitted with probability βnh.
Results
We ran the model as described above for 100 days, under various scenarios to
reveal the interplay of belief and action under the proposed model. Figures 6 and
7 show a summary output of the model dynamics under contrasting conditions.
In figure 6, we have VAE (Vaccine adverse events) preceding the occurrence
of severe disease events. As expected, VAE become the strongest influence on
vt, keeping E[vt] low with consequences to the attained vaccination coverage at
the end of the simulation. We characterize this behavior as a 'vaccine scare'
behavior.
In a different scenario, figure 7, we observe the effect of severe disease events
occurring in high frequency at the beginning of the epidemics. In this case,
disease scare pushes willingness to vaccinate (vt) to high levels.
The impact of individual beliefs on vaccine coverage is highly dependent
on the visibility of the rare VAE. Figure 8 shows the impact of the media
amplification factor on E[vt] and vaccination coverage after ≈ 14 weeks, for a
infectious disease with psd = 0.1 and pae = 0.075. If no media amplification
occurs, willingness to vaccinate and vaccine coverage are high, as severe disease
events are common and severe adverse events are relatively rare. As vaccine
adverse events are amplified by the media, individual's willingness to vaccinate
at the end of the 14 weeks tend to decrease. Such belief change, however,
has a low impact on the vaccine coverage. The explanation for this is that
vaccine coverage is a cumulative measure and, when VAE appear, a relatively
large fraction of the population had already been vaccinated. These results
8
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Figure 6: Impact of occurrence of adverse vaccination events at the begin-
ning of a vaccination campaign. Top-left: vaccination coverage and vaccine
uptake (×8000 doses);top-right: adverse vaccination and serious disease events;
Bottom-left: willingness to vaccinate (vt) and perceived vaccine safety (st);
Bottom-right: Epidemiological time-series.
suggest that VAE should not strongly impact the outcome of an ongoing mass
vaccination campaign, although it could affect the success of future campaigns.
Fixing amplification at a = 8 and psd = 0.1, we investigated how vt (at
the end of the simulation) and vaccine coverage would be affected by increas-
ing the rate of vaccine adverse events, pae (figure 9). As pae increases above
psd, willingness to vaccinate drops fastly, while vaccine coverage diminishes but
slightly.
Discussion
In the present world of mass media channels and rapid and inexpensive commu-
nications, the spread of information, independent of its quality, is very effective,
leading to considerable uncertainty in public opinions. Vaccinating behavior
dynamics has been modelled in different ways in the recent literature, from be-
haviors that aim to maximize self-interest13 to imitation behaviors1. Perceived
side-effects and effectiveness of vaccination are important factors in people's de-
cision to vaccinate4. In this paper we modeled these perceptions dynamically,
and showed its relevance to decision-making dynamics and the consequences to
the underlying epidemiological system and efficacy of vaccination campaigns.
The process through which people update beliefs which will direct their de-
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Figure 7: Impact of occurrence of adverse vaccination events at the begin-
ning of a vaccination campaign. Top-left: vaccination coverage and vaccine
uptake (×8000 doses);top-right: adverse vaccination and serious disease events;
Bottom-left: willingness to vaccinate (vt) and perceived vaccine safety (st);
Bottom-right: Epidemiological time-series.
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Figure 8: Effect of media amplification factor on vaccination coverage and will-
ingness to vaccinate. Coverage and vt values are averages and standard devia-
tions over the population values in the last week of simulation.
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Figure 9: Vaccine coverage and willingness to vaccinate for vaccines with differ-
ent levels of safety. Coverage and vt values are averages and standard deviations
over the population values in the last week of simulation.
11
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
44
7.
1 
: P
os
te
d 
28
 O
ct
 2
00
8
cisions, was modeled using a Bayesian framework. We trust this approach to
be the most natural one as the Bayesian definition of probability is based on
the concept of belief and Bayesian inference methodology was developed as a
representation human learning behavior8. To further improve the adherence of
our model to realistic human learning and decision making behavior, we have
modeled the probability of getting vaccinated (vt) as a separate random vari-
able whose dynamics was determined by Logarithmic pooling with st and other
probability distributions representing disease scare (dt) and reduced willingness
to vaccinated in the absence of risk(rt).
The usage of logarithmic pooling to combine probability distributions rep-
resenting the key variables in the model, allowed for independent modeling of
decision making, based on vt without decisions interfering with Bayesian in-
ferential process governing the dynamics of individual perception of vaccine
safety(st).
The framework presented here comprises a set of useful tools for an ade-
quate quantitative representation of a common yet complex public-health issue.
These tools include representation of beliefs as Bayesian probabilities, usage of
logarithmic pooling to combine probability distributions representing opinions,
and usage natural conjugate priors to efficiently compute the Bayesian posterior.
This approach allowed a comprehensive treatment of the uncertainty regarding
vaccination behavior in a realistic epidemiological model.
The tools proposed in this work can be easily used as building-blocks to com-
pose more complex models. Extended models might include multiple beliefs as a
joint probability distribution, more layers of decision or multiple, independently
evolving belief systems.
This study has also provided valuable lessons about the relevance of the
availability of unbiased information to the general public through channels which
are both official and trustworthy. The yellow fever scare in Brazil demonstrated
clearly that no official press release is taken at face value, it is always colored by
political issues3. In multiple occasions, people reported to the press that they
would do the exact opposite of what was being recommended by public health
authorities due to their mistrust of such authorities.
Another conclusion of this model, is that if the perception of the disease risks
are well established in the population, leading to a higher initial willingness to
vaccinate, adverse events of vaccination, even when widely publicized by the
media, tend to have less impact on vaccination coverage. VAE are more effective
when happening at the beginning of vaccination campaigns, when they can sway
the opinions of a larger audience. Although disease scare can counteract, to a
certain extent the undesired effects of VAE, public health officials must also be
aware of the risks involved in overusing disease risk information, in vaccination
campaign advertisements since this can lead to a rush towards immunization as
seen in the 2008 Yellow Fever scare in Brazil.
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